Is Pralsetinib available in Hong Kong?

Pralsetinib (Pralsetinib) is the first highly selective rearrangement during transfection (RET) inhibitor currently approved in Hong Kong, China, for the treatment of RET fusion-positive metastatic non-small cell lung cancer. The original drug Platinib has been marketed in China, but it has not yet entered the scope of medical insurance through the relevant regulations of the Medical Insurance Bureau. Patients in need can currently only purchase it at their own expense. The price of each box of 100mg*120 pills may be around 60,000 yuan, which is expensive. Platinib may be sold in local hospitals or pharmacies, and patients can choose by themselves.